Is PSTI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,820 people get PSTI articles and Market Currents by email alert.

Get email alerts on PSTI »

HEADLINES:

Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety and the Chairman of the Charite Berlin-Brandenburg Center for Regenerative Therapies

GlobeNewswire (Wed, 5:30AM)
A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013
A John Hodge • Mon, May 20 • 4 Comments
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia

GlobeNewswire (May 13, 2013)
Pluristem Develops PLX-RAD Cells for Use in Hematology

GlobeNewswire (May 7, 2013)
United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapy
Sharon di Stefano • Tue, Apr 30 • 6 Comments
Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013

GlobeNewswire (Apr 30, 2013)
Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension

GlobeNewswire (Apr 29, 2013)
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine

GlobeNewswire (Apr 18, 2013)
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

GlobeNewswire (Apr 11, 2013)
The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy
Brian Nichols • Wed, Apr 10 • 28 Comments
Pluristem Announces Scientific and Investment Conferences for April 2013

GlobeNewswire (Apr 10, 2013)
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
The Future Of Medicine: A Look At 5 Stem Cell Companies
Craig Keolanui • Fri, Mar 22 • 4 Comments
Phase II Trials Will Be Pivotal For These Stem Cell Companies
Ryan's View • Wed, Mar 20 • 11 Comments
Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury

GlobeNewswire (Mar 20, 2013)
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
2012 Stem Cell Standouts And The Outlook For 2013
The Swiss Trader • Thu, Feb 28 • 11 Comments

To learn more about Seeking Alpha Pro, click here.

United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapy
Sharon di Stefano • Tue, Apr 30 • 6 Comments
New Orphan Drug Designation For Pluristem Could Gain Access To FDA 'Progressive Approval'
Sharon di Stefano • Wed, Feb 27 • 4 Comments
Formation Of A New Expert Group Moves Pluristem Into The Expansive Hematology Field
Sharon di Stefano • Wed, Dec 5, 2012 • 39 Comments
Pluristem Standardizes Stem Cell Therapy, Opening Door To The Future Of Medicine
Sharon di Stefano • Mon, Nov 5, 2012 • 12 Comments
Broad Markets, Big Money, Harmful Drugs - Pluristem Takes On The Blockbusters
Ray Dirks • Mon, Sep 10, 2012 • 12 Comments
Pluristem Therapeutics Shoots From The Hip, Moving Toward The Sports Medicine And Muscle Regeneration Markets
Ray Dirks • Tue, Aug 21, 2012 • 6 Comments
Pluristem's Cell Therapy For Bone Marrow A Blockbuster In The Making
Ray Dirks • Wed, Aug 8, 2012 • 24 Comments
Pluristem: 2 Cases Enough To Raise Investor Curiosity?
Prohost Biotech • Mon, Aug 6, 2012 • 10 Comments
Well Funded Pluristem Adds Another Blockbuster Indication To Potent Pipeline
Ray Dirks • Wed, Aug 1, 2012 • 9 Comments
Maxim Group Initiates Coverage Of Pluristem With A Buy
Scott Matusow • Wed, Jul 25, 2012 • 10 Comments
Stem Cell Therapy: The Investment Of The Future
Scott Matusow • Fri, Jul 20, 2012 • 75 Comments
Pluristem Therapeutics' Answer To Big Pharma's Question: What Do We Do Now?
Ray Dirks • Wed, Jul 18, 2012 • 4 Comments
Pluristem Pioneering Intramuscular Placenta-Based Cell Therapies
Len Zehr • Tue, Jul 3, 2012 • 4 Comments
Earnings Preview: Pluristem Therapeutics
Vytautas Drumelis • Tue, Jun 19, 2012
Pluristem's Placental-Derived Cells In The Treatment Of Cardiac Disease
Zami Aberman • Tue, May 29, 2012 • 8 Comments
Pluristem Therapeutics' New Indication May Boost Company Valuation
Ray Dirks • Thu, May 17, 2012 • 12 Comments
Investors Waking Up To Pluristem's Developments
Ray Dirks • Thu, May 10, 2012 • 11 Comments
Pluristem Potential Outweighs Risk
Modernist • Thu, Mar 22, 2012 • 4 Comments
Pluristem Therapeutics: Plant Scale-Up, Outstanding Heart Tissue Data Signal Buy Opportunity
Ray Dirks • Wed, Mar 21, 2012
Pluristem Vs. Geron: An Insider's View Of The Stem Cell Story
Zami Aberman • Mon, Dec 19, 2011 • 17 Comments

A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013
A John Hodge • Mon, May 20 • 4 Comments
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy
Brian Nichols • Wed, Apr 10 • 28 Comments
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
The Future Of Medicine: A Look At 5 Stem Cell Companies
Craig Keolanui • Fri, Mar 22 • 4 Comments
Phase II Trials Will Be Pivotal For These Stem Cell Companies
Ryan's View • Wed, Mar 20 • 11 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
2012 Stem Cell Standouts And The Outlook For 2013
The Swiss Trader • Thu, Feb 28 • 11 Comments
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
3 Regenerative Medicine Companies That Could Deliver In 2013
A John Hodge • Tue, Jan 22 • 18 Comments
Stem Cells, Dr. Oz And A Potentially Lucrative Investment Opportunity
Charles Moscoe • Wed, Jan 2 • 32 Comments
Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid
Ben Yoffe • Tue, Dec 4, 2012 • 36 Comments
4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce
MarketScanners • Tue, Nov 20, 2012 • 11 Comments
An Exciting Week In Cell Therapy
The Swiss Trader • Mon, Nov 12, 2012 • 13 Comments
$33,000 Portfolio: Mostly Cash Ahead Of Elections And Snow-Hurricanes
Joe Springer • Tue, Oct 30, 2012 • 23 Comments
Dilution Is The Solution To Pollution
Eric Wick • Tue, Oct 9, 2012 • 22 Comments
5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments
Scott Matusow • Tue, Oct 9, 2012 • 14 Comments
Mr. Market's Stem Cell Roulette
Brian L. Wilson • Fri, Oct 5, 2012 • 37 Comments

There are no Transcripts on PSTI.

Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety and the Chairman of the Charite Berlin-Brandenburg Center for Regenerative Therapies

GlobeNewswire (Wed, 5:30AM)
Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia

GlobeNewswire (May 13, 2013)
Pluristem Develops PLX-RAD Cells for Use in Hematology

GlobeNewswire (May 7, 2013)
Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013

GlobeNewswire (Apr 30, 2013)
Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension

GlobeNewswire (Apr 29, 2013)
Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine

GlobeNewswire (Apr 18, 2013)
United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

GlobeNewswire (Apr 11, 2013)
Pluristem Announces Scientific and Investment Conferences for April 2013

GlobeNewswire (Apr 10, 2013)
Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury

GlobeNewswire (Mar 20, 2013)
After-Hours Buzz: EA, BAC, DFS & More

at CNBC.com (Mar 18, 2013)
United Therapeutics Moves Forward Towards a Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

GlobeNewswire (Feb 26, 2013)
Pluristem Therapeutics, Inc. Announces Its Sr. VP of Corporate Development Will Be Presenting at the Accredited Members Spring Micro Cap Investor Conference in Las Vegas

Marketwire (Feb 25, 2013)
Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia

GlobeNewswire (Feb 21, 2013)
CORRECTING AND REPLACING -- Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13

GlobeNewswire (Feb 13, 2013)
Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13

GlobeNewswire (Feb 13, 2013)
Pluristem Takes Possession of and Moving Into New State-of-the-Art Manufacturing Facility

GlobeNewswire (Jan 30, 2013)
Pluristem Updates Cell Manufacturing Industry on Its Proprietary 3D Cell Expansion Technology at Industry Conference

GlobeNewswire (Jan 22, 2013)
Pluristem Receives Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Germany

GlobeNewswire (Jan 15, 2013)
Pluristem's CEO Letter to Shareholders

GlobeNewswire (Jan 7, 2013)
Pluristem Initiates Final Validation of New Manufacturing Facility

GlobeNewswire (Dec 27, 2012)

PSTI vs. ETF Alternatives

Company Description

Currently, there's no company description for PSTI.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 11:02 AM Pluristem Therapeutic (PSTI +1%) ticks higher after reporting its PLX cells tested in preclinical animal models of preeclampsia effectively improved several parameters of the disease. Details of the study will be presented on May 30th at the Society for Gynecological Investigation Summit in Jerusalem. Comment! [Healthcare, On the Move]
Wednesday, April 24, 9:11 AM Premarket gainers: BKI +26%. PBTH +11%. LL +7%. PSTI +5%.
Losers: VOCS -31%. UIS -20%. EW -19%. RES -13%. AWAY -9%. SCON -9%. JNPR -7%. SVU -7%. PNRA -6%. CREE -6%. Comment! [On the Move]
Thursday, April 18, 12:09 PM Pluristem Therapeutics (PSTI -1.4%) expands its presence in the orthopedic and sports medicine markets with plans to initiate a Phase I clinical trial to evaluate the safety and efficacy of the local administration of PLX cells to patients suffering from injuries to tendons. PSTI believes that its PLX-PAD cells will improve the post-operative structural and functional status of the rotator cuff. Comment! [Healthcare]
Thursday, April 11, 11:15 AM United Therapeutics (UTHR +0.1%) says it's received approval to perform a human Phase I study in Australia using Pluristem Therapeutics' (PSTI +1.6%) PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension. United Therapeutics and Pluristem entered into a licensing agreement in 2011 that allows UTHR to develop, market and sell PSTI's PLX-PAD cells. 1 Comment [Healthcare, On the Move]
Wednesday, March 20, 8:56 AM Pluristem Therapeutics (PSTI) says the first group of six patients have received its PLacental Expanded cells or a placebo in a Phase I/II trial to test the therapy for treating surgically induced muscle injury. None of the patients have suffered significant side effects so far. Three groups of six patients will be enrolled in the trial. Shares +2% in Tel Aviv. (PR) Comment! [Healthcare]
Wednesday, February 20, 2:32 PM Pluristem Therapeutics (PSTI +4%) pops on reports that the FDA has granted orphan status for its PLX Cells to treat aplastic anemia. 1 Comment [Healthcare, On the Move]
Tuesday, January 15, 8:34 AM Pluristem Therapeutics (PSTI) climbs 6.5% after the developer of placenta-derived cell therapies receives German approval to start a Phase II study of its PLX-PAD cells in patients with Intermittent Claudication (IC), a subset of Peripheral Artery Disease that is characterized by muscle pain, numbness and fatigue, especially in the calf muscle. Around 14M people suffer from IC in the U.S. 1 Comment [Healthcare, On the Move]
Wednesday, November 21, 2012, 12:08 PM Pluristem (PSTI +2.5%) says the FDA has acknowledged that aplastic anemia is a rare disease, confirming that potential treatments for the condition are eligible for orphan drug status. However, it also has requested that PSTI provide additional information and data for further analysis before the agency can determine if PLX cells can qualify for orphan drug designation for aplastic anemia. PSTI is focusing on the use of the cells to treat systemic diseases eliminate the need to use the intravenous route. 3 Comments [Healthcare, On the Move]
Friday, November 9, 2012, 9:10 AM Premarket gainers: ZIP +27%. KYAK +26%. LGF +9%. ENR +8%. PSTI +8%. IGT +7%. WCRX +6%. ISIS +5%.
Losers: GRPN -23%. MTG -15%. ARRY -12%. PGRX -12%. SPRD -10%. JCP -8%. PVR -6%. CPIX -5%. DIS -5%. 1 Comment [On the Move]
Friday, November 9, 2012, 9:04 AM Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says the second of three patients given PSTI’s experimental stem cells died after the company touted the treatments as “life-saving." PSTI wants Bloomberg to publish a correction because the article is "factually inaccurate and misleading." 4 Comments [Healthcare, On the Move]
Thursday, November 8, 2012, 9:10 AM Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%. Comment! [On the Move]
Tuesday, November 6, 2012, 9:11 AM Premarket gainers: JIVE +14%. ROSG +9%. PSTI +8%. ACAD +7%. MIPS +6%. LF +6%. CTRP +5%. VRNG +5%.
Losers: SREV -33%. Z -16%. ESRX -11%. FOSL -10%. VVUS -5%. NVO -5%. Comment! [On the Move]
Wednesday, October 17, 2012, 11:18 AM Pluristem Therapeutics (PSTI +1%) gains after saying that preclinical and in in-vitro studies using it's Placental expanded cells resulted in a reduction of fibrotic processes. The data will be presented at the 3rd Annual Meeting of the Israel Society for Placenta Research on October 18. Comment! [Healthcare]
Thursday, September 13, 2012, 10:39 AM Pluristem Therapeutics (PSTI -13.6%) takes a hit after pricing its offering of 8M units at $4 each, a 12% discount to yesterday's close. The units each include one share of common stock and a warrant to purchase 0.35 of a share. 3 Comments [Healthcare, On the Move]
Thursday, September 13, 2012, 9:10 AM Premarket gainers: EQIX +14%. VICL +13%. APRI +13%. LRN +10%. PLL +7%. CTIC +5%.
Losers: CCRT -29%. PSTI -17%. FMER -7%. USG -6%. HK -5%. 1 Comment [On the Move]
Wednesday, September 12, 2012, 4:56 PM Pluristem Therapeutics (PSTI) says it intends to offer an undisclosed sum of common stock and warrants. Jefferies is acting as sole book-running manager, with Oppenheimer acting as co-lead. The company plans to use the funds to conduct clinical trials, research and product development activities and for general corporate purposes. Shares -11.8% AH. Comment! [Healthcare, On the Move]

willg101
Nice day for $PSTI today
18 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

richardod
?started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back. buying $ATHX do not see more winners suggestions?
Mar 28, 5:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
Add a reply...

140 characters

richardod
started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back buying ATHX do not see more winners - $CUR? ++?
Mar 28, 5:48 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

willg101
$PSTI - short term prospects are not looking too bad. http://seekingalpha.com/a/rrcz
Mar 22, 1:13 PM
Reply (6)

• !Report Abuse
View all 6 replies
nsahbti: Cont. > I honestly don't know how to calculate the value but their patents will be used in a huge number of applications, again, about 1.5 y
Mar 25, 9:29 AM
• !Report Abuse
willg101: ok, who are the Big ones are lining up to buy ?
Mar 26, 10:22 AM
• !Report Abuse
Add a reply...

140 characters

Robbster
Biotech holds include $ARQL, $CUR, $GALE, $IMUC, $NBS, $PSTI, $ STEM, $NLNK. Questioning ARQL, NLNK, but holding for now...
Mar 12, 10:21 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

willg101
$PSTI whats up with the Vol 1M Anyone know what is going on?
Feb 28, 10:13 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

pagreen1966
Are the rumours true that $PSTI has been awarded orphan drug status by the fda?
Feb 20, 3:56 PM
Reply (2)

• !Report Abuse
View all 2 replies
scubastevo80: Yes - its been confirmed on the FDA website that their cells were designated orphan status for treatment of aplastic anemia
Feb 20, 6:29 PM
• !Report Abuse
willg101: Why the drop today ?
Feb 25, 10:23 AM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

willg101
$PSTI - Average Recommendation: Buy Average Target Price: 6.00 SO WHY THE DROP !!!
12/27/12
Reply (1)

• !Report Abuse
View all 1 replies
jomif8301: The several pieces of negative news, and lack of new news has allowed it to spiral down. I'm still long and buying at these lower prices.
12/28/12
• !Report Abuse
Add a reply...

140 characters

jimbo-hawks
why is $PSTI up 16% after-hours?
12/11/12
Reply (1)

• !Report Abuse
View all 1 replies
willg101: Mus be time to buy more $PSTI
12/13/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

richardod
?started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back. buying $ATHX do not see more winners suggestions?
Mar 28, 5:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
Add a reply...

140 characters

willg101
$PSTI - short term prospects are not looking too bad. http://seekingalpha.com/a/rrcz
Mar 22, 1:13 PM
Reply (6)

• !Report Abuse
View all 6 replies
nsahbti: Cont. > I honestly don't know how to calculate the value but their patents will be used in a huge number of applications, again, about 1.5 y
Mar 25, 9:29 AM
• !Report Abuse
willg101: ok, who are the Big ones are lining up to buy ?
Mar 26, 10:22 AM
• !Report Abuse
Add a reply...

140 characters

pagreen1966
Are the rumours true that $PSTI has been awarded orphan drug status by the fda?
Feb 20, 3:56 PM
Reply (2)

• !Report Abuse
View all 2 replies
scubastevo80: Yes - its been confirmed on the FDA website that their cells were designated orphan status for treatment of aplastic anemia
Feb 20, 6:29 PM
• !Report Abuse
willg101: Why the drop today ?
Feb 25, 10:23 AM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

willg101
$PSTI - Average Recommendation: Buy Average Target Price: 6.00 SO WHY THE DROP !!!
12/27/12
Reply (1)

• !Report Abuse
View all 1 replies
jomif8301: The several pieces of negative news, and lack of new news has allowed it to spiral down. I'm still long and buying at these lower prices.
12/28/12
• !Report Abuse
Add a reply...

140 characters

jimbo-hawks
why is $PSTI up 16% after-hours?
12/11/12
Reply (1)

• !Report Abuse
View all 1 replies
willg101: Mus be time to buy more $PSTI
12/13/12
• !Report Abuse
Add a reply...

140 characters

nsahbti
PSTI girl dies not long after treatment was announced successful, company kept quiet on this. Just sold all my PSTI
11/8/12
Reply (10)

• !Report Abuse
View all 10 replies
nsahbti: So why did they not tell the same thing to non Hebrew reading investors?
11/9/12
• !Report Abuse
willg101: poorly researched report http://yhoo.it/TeL4tl
11/9/12
• !Report Abuse
Add a reply...

140 characters

nsahbti
PSTI what is the cause of this massive sell-off???
11/8/12
Reply (6)

• !Report Abuse
View all 6 replies
sheths: ... and insider sells
11/8/12
• !Report Abuse
willg101: 1-Star Biotech Stocks Poised to Plunge: Pluristem Therapeutics?
11/8/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
Here's the latest $33,000 article, we stand at $35,814.50 http://seekingalpha.com/a/kltb $PSTI $SPPI $ARNA $ACI $MNKD $IBIO $ATRS #Sandy
10/30/12
Reply (3)

• !Report Abuse
View all 3 replies
Joe Springer: Hi IV, May 25 was start, I try to limit the trades so that it is replicable, 2 month average per trade about: http://seekingalpha.com/p/e7pf
10/30/12
• !Report Abuse
sundate36: Is anyone buying ARNA at 8.00 today?
10/31/12
• !Report Abuse
Add a reply...

140 characters

The Berenstain Bulls
Still long NBS, PSTI, NVLX. NVLX: http://on.mktw.net/MwvxpE
7/18/12
Reply (7)

• !Report Abuse
View all 7 replies
The Berenstain Bulls: @iadops40: Thank you, I will keep an eye on it.
10/24/12
• !Report Abuse
iadops40: lol, I sold that mid September, before the scandal
10/24/12
• !Report Abuse
Add a reply...

140 characters

The Berenstain Bulls
PSTI is on sale, imo, long. http://bit.ly/K2JxBu http://reut.rs/LoLbQk http://yhoo.it/Jfn5Xm
5/23/12
Reply (2)

• !Report Abuse
View all 2 replies
Robbster: Oh, yeah. There are only two biotechs that I am confident represent real breakthrough new capability, PSTI is one, IMUC is the other.
5/24/12
• !Report Abuse
The Berenstain Bulls: @Robbster: thank you for the heads up - I will check out IMUC.
10/24/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$33,000 Portfolio -- Selling biotech to put proceeds in $MNKD, love the price and they are funded now, more to come $PSTI $IBIO $ATRS $ACI
10/18/12
Reply (5)

• !Report Abuse
View all 5 replies
joe kelly: As a percentage of portfolio, how large is the MNKD investment Joe?
10/19/12
• !Report Abuse
Joe Springer: That would put it in the 20% range roughly, I have to do the math Joe
10/19/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Hearing that $PSTI will soon hear from FDA in regards to their filed request for Orphan Drug Status for #Aplastic anemia #DD
10/10/12
Reply (1)

• !Report Abuse
View all 1 replies
DANDISIK: Scott, I have 2 Questions :1.) is $AMRN now a sinking ship ? 2.) Would you recommend buying $PSTI at ~ $4.00 now ? if not then what price ?
10/10/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
According to @biomedreports, they think $PSTI should be hearing good news soon on orphan drug status -- aplastic bone marrow
10/9/12
Reply (4)

• !Report Abuse
View all 4 replies
wiesemc: Are you a premium member of biomedreports, Scott?
10/10/12
• !Report Abuse
Scott Matusow: yes
10/10/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
If @BioMedreports is right, I would expect a minimum move to $5 - $6 if Pivitol clinical news included, Institutions would come in. $PSTI
10/9/12
Reply (4)

• !Report Abuse
View all 4 replies
IronmanVR4: What going on with ZGNX Scott? You still holding this? Time to dump or buy more?
10/9/12
• !Report Abuse
sheldond: PSTI is looking like a winner. Orphan status would be awesome. LONG PSTI
10/9/12
• !Report Abuse
Add a reply...

140 characters

PSTI Pluristem Therapeutics, Inc.

PSTI

Pluristem Therapeutics, Inc.